Ipamorelin Cost in the US

If you go looking for what ipamorelin costs, you’ll find numbers that don’t agree with each other — under $100 a month on some peptide sites, around $200 at a telehealth clinic, and several hundred per cycle at an in-person practice. The spread isn’t random, and it isn’t really about ipamorelin. It comes from one fact that shapes everything on this page: ipamorelin is almost never sold by itself. Understanding why is the key to reading any price you’re quoted.

Why there’s no single price for ipamorelin

Like most peptides in this category, ipamorelin has no list price the way a pharmacy-stocked brand drug does. It isn’t an FDA-approved medication, there’s no insurance-negotiated rate, and there’s no national retail benchmark. What you pay is set by the channel you go through and the oversight that comes with it — not by the molecule, which is cheap to manufacture.

That means a low number and a high number can describe completely different things: one might be a bare vial with no prescriber attached, another a monthly program that includes a consultation, lab review, and follow-up. Comparing them as if they’re the same product is the most common mistake people make. Price here tracks the service wrapped around the peptide, so the first question to ask about any quote is what’s actually included.

The one thing that changes everything: you’re rarely buying ipamorelin alone

Ipamorelin is a selective growth-hormone-releasing peptide (a GHRP). In practice, providers almost always pair it with a GHRH analog — usually CJC-1295 — because the two act on different receptors and are thought to produce a cleaner growth-hormone pulse together than either does alone. The upshot for your wallet is simple: the “ipamorelin” price you find is, the overwhelming majority of the time, the price of a CJC-1295 + ipamorelin combo.

This is why a standalone “ipamorelin per month” figure is so hard to pin down — it’s a slightly artificial number. Clinics quote the stack. When a telehealth program advertises a CJC-1295/ipamorelin combo at around $200 a month, ipamorelin’s own share of that is a fraction of the total; the larger drivers are the second peptide and, far more than either, the provider relationship. So if your goal is to budget, budgeting for ipamorelin in isolation is the wrong frame. Budget for the program. (For how the two peptides actually differ in role and evidence, see CJC-1295 vs ipamorelin; for the partner’s pricing, CJC-1295 cost.)

What you’re actually paying for (unbundling the bill)

A monthly or per-cycle peptide price is really four separate things bundled into one number:

• The medication itself. This is the cheapest component. The raw peptide is inexpensive to produce, which is exactly why “research” vials can be sold for the price of a restaurant meal.
• The prescriber relationship. This is where most of a legitimate bill goes — the consultation, the clinical judgment, the willingness of a licensed provider to evaluate you and stand behind a plan. It’s the part you can’t buy from a vial vendor, and it’s the main reason a $200 program costs more than a $50 vial.
• Labs and monitoring. Highly variable. Some telehealth quotes exclude bloodwork entirely; comprehensive clinics build a baseline panel and follow-up testing into the price. Two programs at the “same” price can differ enormously here.
• Channel legitimacy. The least visible line item. A price that includes a real prescription, a licensed pharmacy, and oversight is buying you something a gray-market vial can’t: traceability and recourse. With ipamorelin specifically, this item is unusually fraught — see below.

When you see a very low number, it’s almost always because one or more of these was stripped out — usually the prescriber, the labs, and the channel legitimacy all at once.

Route-by-route: what each path costs

Telehealth combo programs (the realistic mainstream route)

This is how most people actually access ipamorelin, and it’s bundled as the CJC-1295/ipamorelin stack. Programs commonly land in the ~$150-$400/month range, with the lower end covering the compounded peptide and a brief, often asynchronous consultation, and the upper end adding more provider contact. Subscription clinics that lock you into a membership tend to sit higher — roughly $250-$400/month — in exchange for ongoing access. The cheaper the quote, the more likely it excludes labs, injection supplies, and body-composition tracking, which you’d then pay for separately.

Note: A headline telehealth price is a floor, not a total. Ask specifically whether bloodwork, supplies, and follow-up visits are included before comparing two programs.

In-person clinics

Practices that see you in person generally cost more, and many quote per cycle rather than per month. A standalone GH-peptide cycle can run a few hundred dollars, with two-peptide stacks priced higher (some clinics quote in the $400-$800 per cycle range for a stack, all-inclusive of the consult and protocol). You’re paying for in-person evaluation, drawn-and-reviewed labs, and a defined clinical relationship — the things that make the higher number mean something.

”Research-only” vials

Peptide websites list ipamorelin vials for roughly $40-$95 each, and CJC-1295/ipamorelin combinations sometimes work out to under $150/month on paper. Treat these as a different universe, not a discount. They are sold “for research use only,” explicitly not for human use, with no prescription, no compounding pharmacy, and no clinical oversight. That “saving” is the entire safety and legitimacy layer removed. You can’t verify the dose, the purity, or whether the vial even contains what the label claims — so a cheap vial isn’t cheap ipamorelin, it’s an unknown substance at a low price. This is not a legitimate patient route, and most of the apparent cost advantage is the absence of everything that makes a medication a medication. (More on why in research peptides explained and are peptides legal in the US?.)

Why ipamorelin has no cheap “compounded” tier in 2026

For some peptides, a patient-specific 503A compounding pharmacy can legally prepare the medication, which creates a defensible mid-range price. Ipamorelin’s situation in mid-2026 is worse than that, and it directly affects cost.

Ipamorelin was referred to the FDA’s Pharmacy Compounding Advisory Committee (PCAC) in 2024 — and the committee voted against adding it to the 503A bulk drug substances list (alongside CJC-1295, AOD-9604, and thymosin alpha-1) at meetings in late 2024. It was not among the twelve peptides the FDA removed from Category 2 in April 2026, and it is not on the July 2026 PCAC docket (BPC-157, KPV, TB-500, MOTS-C, DSIP, Semax, Epitalon) or the early-2027 review list (GHK-Cu, Melanotan II, LL-37, Dihexa, PEG-MGF). In plain terms: there is no clear, near-term pathway for a compounding pharmacy to legally add ipamorelin to its bulks list.

The pricing consequence is real. Where a pharmacy compounds ipamorelin anyway, part of what you’re paying absorbs that regulatory uncertainty, and supply can be unstable — a program that exists today may change if enforcement tightens. So unlike a peptide with a clean compounding route, ipamorelin has no settled “legitimate compounded” price band you can anchor to. Don’t assume the figure you’re quoted is durable. (For how 503A and 503B actually work, see compounded peptides: 503A vs 503B; for the full regulatory timeline, the 2026 FDA peptide reclassification.)

Cheaper, cleaner legal alternatives

Because ipamorelin sits in this gray zone, the more useful cost comparison is often against the GH-support peptides on firmer legal ground:

• Sermorelin is the obvious benchmark. It’s a GHRH analog with a cleaner compounding status and telehealth pricing that frequently starts around $96-$225/month — comparable to or below a CJC/ipamorelin program, with less regulatory risk attached. A combination protocol can add a modest amount on top, but the base is competitive. See sermorelin cost.
• Tesamorelin is more expensive — compounded versions run roughly $150-$300/month, and the FDA-approved brand (Egrifta) costs far more without insurance because it’s approved only for a specific HIV-related indication. But it’s the one option in this family with a genuine FDA approval behind it.

The point isn’t that ipamorelin is dramatically pricier — it usually isn’t. It’s that ipamorelin rarely wins on cost and legitimacy at the same time. If price is your deciding factor, sermorelin generally gives you a cleaner version of the same idea for similar money.

Insurance, HSA/FSA, and discount cards

Plan for $0 of insurance help. Ipamorelin for wellness, anti-aging, recovery, or body composition is not an approved drug for those uses, and neither commercial plans nor Medicare reimburse it — the same way they don’t cover sermorelin or compounded GH peptides for these purposes. (This is in contrast to FDA-approved GLP-1 weight-loss drugs, which insurance does sometimes touch; peptides like ipamorelin are a different category entirely.)

Two partial offsets exist, neither guaranteed:

• HSA/FSA dollars may cover a peptide prescribed by a licensed clinician as a qualified medical expense, effectively discounting it by your marginal tax rate. Confirm eligibility with your provider and plan administrator first — it’s plausible, not automatic.
• GoodRx and pharmacy discount cards do not apply. Those work on commercially manufactured drugs, not compounded peptides, so don’t budget around them.

Cost red flags

A few signals that a price is too good for the wrong reasons:

• A standalone “ipamorelin” deal with no prescriber. If no licensed clinician is evaluating you, you’re buying a vial, not care — and likely a “research” product.
• “No consult required” or instant checkout. The consultation is the part of a legitimate bill you actually want; its absence is a discount on safety.
• Prices quoted in dollars-per-milligram with an order button. That’s a vendor framing a research chemical as a bargain, not a clinic pricing a treatment.
• A figure that seems durable for a peptide in legal limbo. Given ipamorelin’s compounding status, treat any “locked-in” long-term price with skepticism.

The honest bottom line: there’s no clean single price for ipamorelin because there’s rarely a clean single product. Decide what you’re actually buying — a real provider relationship and a legitimate channel, or a cheap vial of something unverified — and the price differences stop looking confusing. For how to find a legitimate provider in the first place, start with how to get ipamorelin and ipamorelin prescription: how to get one.